Previous 10 | Next 10 |
2024-01-02 12:32:58 ET More on Corcept Therapeutics Analyzing Corcept's Strategic Shift In A Competitive Pharma Landscape Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript Biggest stock movers today: Apple, Unity Software, Li Auto, crypto-rela...
2024-01-02 10:00:09 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...
MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the horm...
2024-01-02 06:48:18 ET Summary Number of electric vehicle models eligible for $7,500 tax credit in the US has fallen due to tighter rules on sourcing parts from Chinese suppliers. Bitcoin surpasses $45,000 for the first time in two years, driven by anticipation of US approval of a...
2024-01-01 21:34:53 ET Analyzing Corcept's Strategic Shift In A Competitive Pharma Landscape Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript Truist upgrades Corcept to buy, cites market potential for relacorilant Corcept Therapeutics Q3 ...
2023-11-30 03:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-13 13:58:11 ET Summary Corcept Therapeutics' strategic shift to relacorilant from Korlym addresses efficacy and safety, amidst Teva's patent dispute. Financially robust with 21.5% YOY revenue growth; however, increasing R&D costs and potential generic competition are c...
2023-11-06 16:06:39 ET More on Corcept Therapeutics Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade) Corcept Therapeutics Q3 2023 Earnings Preview Corcep...
2023-11-01 20:44:01 ET Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript November 01, 2023 05:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Off...
2023-11-01 16:28:19 ET More on Corcept Therapeutics Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade) Corcept Therapeutics Q3 2023 Earnings Preview Corcept Therapeutics plunges amid patent trial with Teva (update) Seeking Alpha&...
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
NASDAQ Market:
2024-05-02 17:30:02 ET Truist Financial analyst issues BUY recommendation for CORT on May 2, 2024 04:01PM ET. The previous analyst recommendation was Buy. CORT was trading at $25.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of th...